Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

Pharmacogenomics

Volumn 6, Issue 4, 2005, Pages 357-371

  Lee, Su Jun ^a   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CYP3A4; CYP3A5; Genotyping; Metabolism pharmacogenetics; Pharmacogenetics; Polymorphisms; Single nucleotide polymorphisms

Indexed keywords

7 BENZYLOXY 4 (TRIFLUOROMETHYL)COUMARIN; 7,8 DIHYDRO 7,8 DIHYDROXYBENZO[A]PYRENE; AFLATOXIN B1; ANDROSTENEDIONE; ATORVASTATIN; CHLORPYRIFOS; COUMARIN DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIAZEPAM; ERYTHROMYCIN; ESTRADIOL; HYDROCORTISONE; IFOSFAMIDE; INDINAVIR; KETOCONAZOLE; LITHOCHOLIC ACID; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; PARACETAMOL; PROGESTERONE; QUINIDINE; RITONAVIR; SIMVASTATIN; TACROLIMUS; TESTOSTERONE; TRIAZOLAM; UNCLASSIFIED DRUG; VERAPAMIL;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALLELE; CATALYSIS; DRUG METABOLISM; DRUG SAFETY; ENZYME MECHANISM; ENZYME SPECIFICITY; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LIVER; MOLECULAR GENETICS; NOMENCLATURE; NUCLEOTIDE SEQUENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 21444440076     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.4.357     Document Type: Review

References (112)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
2. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83-448 (2002).
3. Guengerich FP: Cytochrome P450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).
4. Wrighton SA, Brian WR, Sari MA et al.: Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213 (1990).
5. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
6. Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP: Isolation and sequence determination of a cDNA clone related to human cytochrome P450 nifedipine oxidase. Proc. Natl Acad. Sci. USA 83, 8064-8068 (1986).
7. Molowa DT, Schuetz EG, Wrighton SA et al.: Complete cDNA sequence of a cytochrome P450 inducible by glucocorticoids in human liver. Proc. Natl Acad. Sci. USA 83, 5311-5315 (1986).
8. Aoyama T, Yamano S, Waxman DJ et al.: Cytochrome P450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 264, 10388-10395 (1989).
9. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M: Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36, 97-105 (1989).
10. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27, 383-391 (2001).
11. Burk O, Tegude H, Koch I et al.: Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277, 24280-24288 (2002).
12. Burk O, Wojnowski L: Cytochrome P450 3A and their regulation. Naunyn Schmiedeberg Arch. Pharmacol. 369, 105-124 (2004).
13. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
14. Williams JA, Ring BJ, Cantrell VE et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30, 883-891 (2002).
15. Nelson DR, Koymans L, Kamataki T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996).
16. Ingelman-Sundberg M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. 369, 89-104 (2004).
17. Hustert E, Haberl M, Burk O, et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779 (2001).
18. Wolbold R, Klein K, Burk O, et al.: Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38, 978-988 (2003).
19. Wilkinson GR: Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm. 24, 475-490 (1996).
20. Lin YS, Lockwood GF, Graham MA et al.: In vivo phenotyping for CYP3A by a single-point determination of midazolain plasma concentration. Pharmacogenetics 11, 781-791 (2001).
21. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878 (1992).
22. Inoue K, Inazawa J, Nakagawa H et al.: Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn. J. Hum. Genet. 37, 133-138 (1992).
23. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59, 386-392 (2001).
24. Gonzalez FJ, Schmid BJ, Umeno M et al.: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7, 79-86 (1988).
25. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS: Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029-1036 (1987).
26. Kolars JC, Lown KS, Schmiedlin-Ren P et al.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4, 247-259 (1994).
27. Finnstrom N, Bjelfman C, Soderstrom TG et al.: Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest. 31, 880-886 (2001).
28. Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2, 9-39 (2001).
29. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 104, 1-8 (1995).
30. Waxman DJ, Lapenson DP, Aoyama T et al.: Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290, 160-166 (1991).
31. Omiecinski CJ, Remmel RP, Hosagrahara VP: Concise review of the cytochrome P450s and their roles in toxicology. Toxicol. Sci. 48, 151-156 (1999).
32. Gonzalez FJ, Gelboin HV: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26, 165-183 (1994).
33. Fukushima-Uesaka H, Saito Y, Watanabe H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23, 100 (2004).
34. Amirimani B, Walker AH, Weber BL, Rebbeck TR: Response: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 91, 1588-1590 (1999).
35. Ando Y, Tateishi T, Sekido Y et al.: Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 91, 1587-1590 (1999).
36. Garcia-Martin E, Martinez C, Pizarro RM et al.: CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. 71, 196-204 (2002).
37. Spurdle AB, Goodwin B, Hodgson E et al.: The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12, 355-366 (2002).
38. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M: Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201-205 (1999).
39. Keshava C, McCardies EC, Weston A: CYP3A4 polymorphisms - potential risk factors for breast and prostate cancer: a HuGE review. Am. J. Epidemiol. 160, 825-841 (2004).
40. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271-1294 (2002).
41. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288-294 (1999).
42. Paris PL, Kupelian PA, Hall JM et al.: Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 8, 901-905 (1999).
43. Sata F, Sapone A, Elizondo G et al.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56 (2000).
44. Tayeb MT, Clark C, Sharp L et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol. Rep. 9, 653-655 (2002).
45. Tayeb MT, Clark C, Ameyaw MM et al.: CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 10, 753-756 (2000).
46. Patki KC, von Moltke LL, Harmatz JS et al.: Effect of age on in vitro triazolam biotransformation in male human liver microsomes. J. Pharmacol. Exp. Ther. 308, 874-879 (2004).
47. Wandel C, Witte JS, Hall JM et al.: CYP3A activity in African-American and European-American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin. Pharmacol. Ther. 68, 82-91 (2000).
48. Plummer SJ, Conti DV, Paris PL et al.: CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12, 928-932 (2003).
49. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225-1229 (1998).
50. Felix CA, Walker AH, Lange BJ et al.: Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 95, 13176-13181 (1998).
51. Wojnowski L, Hustert E, Klein K et al.: Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 94, 630-631; author reply 631-632 (2002).
52. Dai D, Tang J, Rose R et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831 (2001).
53. Eiselt R, Domanski TL, Zibat A et al.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458 (2001).
54. Lee SJ, Bell DA, Coulter S, Ghanayem B, Goldstein JA: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J. Pharmacol. Exp. Ther. 313, 302-309 (2005).
55. Hsieh KP, Lin YY, Cheng CL et al.: Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29, 268-273 (2001).
56. Murayama N, Nakamura T, Saeki M et al.: CYP3A4 gene polymorphisms influence cestosterone 6β -hydroxylation. Drug Metab. Pharmacokinet. 17, 150-156 (2002).
57. Lamba JK, Lin YS, Thummel K et al.: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132 (2002).
58. Spurr NK, Gough AC, Stevenson K, Wolf CR: The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter. Hum. Genet. 81, 171-174 (1989).
59. Gellner K, Eiselt R, Hustert E et al.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11, 111-121 (2001).
60. Kivisto KT, Griese EU, Fritz P et al.: Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedebergs Arch. Pharmacol. 353, 207-212 (1996).
61. Haehner BD, Gorski JC, Vandenbranden M et al.: Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol. 50, 52-59 (1996).
62. Schuetz EG, Schuetz JD, Grogan WM et al.: Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch. Biochem. Biophys. 294, 206-214 (1992).
63. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS: Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Dispos. 24, 899-905 (1996).
64. Yamakoshi Y, Kishimoto T, Sugimura K, Kawashima H: Human prostate CYP3A5: identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem. Biophys. Res. Commun. 260, 676-681 (1999).
65. Janardan SK, Lown KS, Schmiedlin-Ren P, Thummel KE, Watkins PB: Selective expression of CYP3A5 and not CYP3A4 in human blood. Pharmacogenetics 6, 379-385 (1996).
66. Lin YS, Dowling AL, Quigley SD et al: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162-172 (2002).
67. Burk O, Koch I, Raucy J et al.: The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem. 279, 38379-38385 (2004).
68. Rae JM, Johnson MD, Lippman ME, Flockhart DA: Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299, 849-857 (2001).
69. Goodwin B, Hodgson E, Liddle C: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339 (1999).
70. Thompson EE, Kuttab-Boulos H, Witonsky D et al.: CYP3A variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75, 1059-1069 (2004).
71. Ho H, Pinto A, Hall SD et al.: Association between the CYP3A5 genotype and blood pressure. Hypertension 45, 294-298 (2005).
72. Yamazaki H, Ueng YF, Shimada T, Guengerich FP: Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 34, 8380-8389 (1995).
73. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ: CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch. Biochem. Biophys. 319, 157-167 (1995).
74. Ingelman-Sundberg M, Hagbjork AL, Ueng YF, Yamazaki H, Guengerich FP: High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influence of membrane charge. Biochem. Biophys. Res. Commun. 221, 318-322 (1996).
75. Domanski TL, Liu J, Harlow GR, Halpert JR: Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. Arch. Biochem. Biophys. 350, 223-232 (1998).
76. Buters JT, Korzekwa KR, Kunze KL et al.: cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab. Dispos. 22, 688-692 (1994).
77. Brian WR, Sari MA, Iwasaki M et al.: Catalytic activities of human liver cytochrome P450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29, 11280-11292 (1990).
78. Patki KC, Von Moltke LL, Greenblatt DJ: In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos. 31, 938-944 (2003).
79. Yamaori S, Yamazaki H, Suzuki A et al.: Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem. Pharmacol. 66, 2333-2340 (2003).
80. Gillam EM, Guo Z, Ueng YF et al.: Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 317, 374-384 (1995).
81. Saeki M, Saito Y, Nakamura T et al.: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat. 21, 653 (2003).
82. Lee SJ, Usmani KA, Chanas B et al.: Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13, 461-472 (2003).
83. Jounaidi Y, Hyrailles V, Gervot L, Maurel P: Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem. Biophys. Res. Commun. 221, 466-470 (1996).
84. Kivisto KT, Niemi M, Schaeffeler E et al.: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14, 523-525 (2004).
85. Goto M, Masuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14, 471-478 (2004).
86. Haufroid V, Mourad M, Van Kerckhove V et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14, 147-154 (2004).
87. Min DI, Ellingrod VL, Marsh S, McLeod H: CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. 26, 524-528 (2004).
88. Wong M, Balleine RL, Collins M et al.: CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther. 75, 529-538 (2004).
89. Wojnowski L, Turner PC, Pedersen B et al.: Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in the Gambia, West Africa. Pharmacogenetics 14, 691-700 (2004).
90. Chou FC, Tzeng SJ, Huang JD: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. 29, 1205-1209 (2001).
91. Givens RC, Lin YS, Dowling AL et al.: CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J. Appl. Physiol. 95, 1297-1300 (2003).
92. Gonzalez CI, Bhattacharya A, Wang W, Peltz SW: Nonsense-mediated mRNA decay in Saccharomyces cerevisiae. Gene 274, 15-25 (2001).
93. Peng SS, Chen CY, Shyu AB: Functional characterization of a non-AUUUA AU-rich element from the c-jun proto-oncogene mRNA: evidence for a novel class of AU-rich elements. Mol. Cell. Biol. 16, 1490-1499 (1996).
94. Ozdemir V, Kalowa W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000).
95. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5, 243-272 (2004).
96. Hiratsuka M, Takekuma Y, Endo N et al.: Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58, 417-421 (2002).
97. Balram C, Zhou Q, Cheung YB, Lee EJ: CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol. 59, 123-126 (2003).
98. Floyd MD, Gervasini G, Masica AL et al.: Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13, 595-606 (2003).
99. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48, 1668-1671 (2002).
100. Hunt CM, Watkins PB, Saenger P et al.: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin. Pharmacol. Ther. 51, 18-23 (1992).
101. Schellens JH, Soons PA, Breimer DD: Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem. Pharmacol. 37, 2507-2510 (1988).
102. Hustert E, Zibat A, Presecan-Siedel E et al.: Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29, 1454-1459 (2001).
103. Zhang J, Kuehl P, Green ED et al.: The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11, 555-572 (2001).
104. Hasselink DA, van Schaik RHN, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74, 245-254 (2003).
105. Fukuen S, Fukuda T, Maune H et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12, 331-334 (2002).
106. Liu T-C, Lin S-F, Chen T-P, Chang J-G: Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol. Reports 9, 327-329 (2002).
107. Shih PS, Huang JD: Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 30, 1491-1496 (2002).
108. King BP, Leathart JBS, Mutch E, Williams FM, Daly AK: CYP3A5 phenotype-genotype correlations in a British population. Br. J. Clin. Pharmacol. 55, 625-629 (2003).
109. Thervet E, Anglicheau D, King B et al.: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76, 1233-1235 (2003).
110. Yates CR, Zhang W, Song P et al.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 43, 555-564 (2003).
111. Song P, Dirks N, Gaber AO et al. Detection of CYP3A5*3 and *6 using real-time PCR. Clin. Pharmacol. Ther. 71, P103 (2002).
112. Westlind-Johnsson A, Malmebo S, Johansson A et al.: Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31, 755-761 (2003).